140 related articles for article (PubMed ID: 34801672)
1. Magnetic resonance molecular imaging of extradomain B fibronectin enables detection of pancreatic ductal adenocarcinoma metastasis.
Qiao PL; Gargesha M; Liu Y; Laney VEA; Hall RC; Vaidya AM; Gilmore H; Gawelek K; Scott BB; Roy D; Wilson DL; Lu ZR
Magn Reson Imaging; 2022 Feb; 86():37-45. PubMed ID: 34801672
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Assessment of the Effectiveness of Magnetic Resonance Molecular Imaging of Extradomain-B Fibronectin for Detection and Characterization of Oral Cancer.
Hall RC; Ayat NR; Qiao PL; Vaidya AM; Ma D; Aminoshariae A; Stojanov I; Lu ZR
Mol Imaging Biol; 2020 Dec; 22(6):1532-1542. PubMed ID: 32789648
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive assessment and therapeutic monitoring of drug-resistant colorectal cancer by MR molecular imaging of extradomain-B fibronectin.
Vaidya A; Ayat N; Buford M; Wang H; Shankardass A; Zhao Y; Gilmore H; Wang Z; Lu ZR
Theranostics; 2020; 10(24):11127-11143. PubMed ID: 33042274
[TBL] [Abstract][Full Text] [Related]
4. Magnetic Resonance Molecular Imaging of Extradomain B Fibronectin Improves Imaging of Pancreatic Cancer Tumor Xenografts.
Qiao P; Ayat NR; Vaidya A; Gao S; Sun W; Chou S; Han Z; Gilmore H; Winter JM; Lu ZR
Front Oncol; 2020; 10():586727. PubMed ID: 33194740
[TBL] [Abstract][Full Text] [Related]
5. Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer.
Lu ZR; Laney V; Li Y
Acc Chem Res; 2022 Oct; 55(19):2833-2847. PubMed ID: 36121350
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Targeted ECO/miR-200c Nanoparticles for Modulating Tumor Microenvironment and Treating Triple Negative Breast Cancer as Non-invasively Monitored by MR Molecular Imaging.
Schilb AL; Ayat NR; Vaidya AM; Hertz LM; Hall RC; Scheidt JH; Sun D; Sun Z; Gopalakrishnan R; Lu ZR
Pharm Res; 2021 Aug; 38(8):1405-1418. PubMed ID: 34389916
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance molecular imaging of metastatic breast cancer by targeting extradomain-B fibronectin in the tumor microenvironment.
Han Z; Cheng H; Parvani JG; Zhou Z; Lu ZR
Magn Reson Med; 2018 Jun; 79(6):3135-3143. PubMed ID: 29082597
[TBL] [Abstract][Full Text] [Related]
8. Effective MR Molecular Imaging of Triple Negative Breast Cancer With an EDB-Fibronectin-Specific Contrast Agent at Reduced Doses.
Ayat NR; Vaidya A; Yeung GA; Buford MN; Hall RC; Qiao PL; Yu X; Lu ZR
Front Oncol; 2019; 9():1351. PubMed ID: 31850230
[TBL] [Abstract][Full Text] [Related]
9. Extradomain-B Fibronectin-Targeted Dextran-Based Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Probe for Detecting Pancreatic Cancer.
Han Z; Zhang S; Fujiwara K; Zhang J; Li Y; Liu J; van Zijl PCM; Lu ZR; Zheng L; Liu G
Bioconjug Chem; 2019 May; 30(5):1425-1433. PubMed ID: 30938983
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticles targeting extra domain B of fibronectin-specific to the atherosclerotic lesion types III, IV, and V-enhance plaque detection and cargo delivery.
Yu M; Ortega CA; Si K; Molinaro R; Schoen FJ; Leitao RFC; Xu X; Mahmoudi M; Ahn S; Liu J; Saw PE; Lee IH; Brayner MMB; Lotfi A; Shi J; Libby P; Jon S; Farokhzad OC
Theranostics; 2018; 8(21):6008-6024. PubMed ID: 30613278
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Efficacy of the Combination of RNAi of lncRNA DANCR with Chemotherapy to Treat Triple Negative Breast Cancer Using Magnetic Resonance Molecular Imaging.
Nicolescu C; Kim J; Sun D; Lu ZR
Bioconjug Chem; 2024 Mar; 35(3):381-388. PubMed ID: 38446033
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Dual-Targeted ECO/siRNA Nanoparticles against an Oncogenic lncRNA for Triple Negative Breast Cancer Therapy with Magnetic Resonance Molecular Imaging.
Nicolescu C; Schilb A; Kim J; Sun D; Hall R; Gao S; Gilmore H; Schiemann WP; Lu ZR
Chem Biomed Imaging; 2023 Aug; 1(5):461-470. PubMed ID: 37655165
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and Assessment of Peptide Gd-DOTA Conjugates Targeting Extradomain B Fibronectin for Magnetic Resonance Molecular Imaging of Prostate Cancer.
Li Y; Han Z; Roelle S; DeSanto A; Sabatelle R; Schur R; Lu ZR
Mol Pharm; 2017 Nov; 14(11):3906-3915. PubMed ID: 28976766
[TBL] [Abstract][Full Text] [Related]
14. MRI of breast tumor initiating cells using the extra domain-B of fibronectin targeting nanoparticles.
Sun Y; Kim HS; Park J; Li M; Tian L; Choi Y; Choi BI; Jon S; Moon WK
Theranostics; 2014; 4(8):845-57. PubMed ID: 24955145
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Extradomain-B Fibronectin is Associated with Invasion of Breast Cancer Cells.
Vaidya A; Wang H; Qian V; Gilmore H; Lu ZR
Cells; 2020 Aug; 9(8):. PubMed ID: 32756405
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Physicochemical Properties, Pharmacokinetics, Biodistribution, Toxicity, and Contrast-Enhanced Cancer MRI of a Cancer-Targeting Contrast Agent, MT218.
Li Y; Gao S; Jiang H; Ayat N; Laney V; Nicolescu C; Sun W; Tweedle MF; Lu ZR
Invest Radiol; 2022 Oct; 57(10):639-654. PubMed ID: 35703463
[TBL] [Abstract][Full Text] [Related]
17. Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma.
Saw PE; Xu X; Kang BR; Lee J; Lee YS; Kim C; Kim H; Kang SH; Na YJ; Moon HJ; Kim JH; Park YK; Yoon W; Kim JH; Kwon TH; Choi C; Jon S; Chong K
Theranostics; 2021; 11(2):941-957. PubMed ID: 33391514
[TBL] [Abstract][Full Text] [Related]
18. CAR-T Therapy Targets Extra Domain B of Fibronectin Positive Solid Tumor Cells.
Tang J; Liu N; Zhu Y; Li Y; Zhao X
Immunol Invest; 2023 Nov; 52(8):985-996. PubMed ID: 37815216
[TBL] [Abstract][Full Text] [Related]
19. Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent.
Zhang W; Liang X; Zhang X; Tong W; Shi G; Guo H; Jin Z; Tian J; Du Y; Xue H
Eur J Nucl Med Mol Imaging; 2024 Feb; ():. PubMed ID: 38372766
[TBL] [Abstract][Full Text] [Related]
20. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1.
Foygel K; Wang H; Machtaler S; Lutz AM; Chen R; Pysz M; Lowe AW; Tian L; Carrigan T; Brentnall TA; Willmann JK
Gastroenterology; 2013 Oct; 145(4):885-894.e3. PubMed ID: 23791701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]